Responses
Oral Plenary
Plenary I
IGCS20_1268
3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
Compose a Response to This Article
Other responses
No responses have been published for this article.